Lazanda is available by prescription only and is used to treat intense flares of pain that occur in people with cancer. This pain medicine is a strong narcotic opioid drug, and has a high potential for abuse. The typical dose of this nasal spray is one or two sprays into the nostril no more than four times a day. Side effects may include nausea, vomiting, and dizziness.
What Is Lazanda?
Lazanda® (fentanyl nasal spray) is a prescription narcotic pain medication approved for the treatment of breakthrough cancer pain. Breakthrough pain is defined as intense flares of pain that "break through" regular, around-the-clock pain medication. Lazanda should only be used by people who have already been taking, and are tolerant to, regularly scheduled narcotic medication for their underlying cancer pain.
Lazanda contains fentanyl, a potent opioid pain medication. Like other medications that contain fentanyl, Lazanda is a Schedule II controlled substance. This means there are strict laws and regulations controlling the use of the medication. Schedule II controlled substances are considered to have the highest abuse potential of all prescription medications.
Because of the potential for abuse and possible overdose, this medication is only available through a restricted program called the Lazanda Risk Evaluation and Mitigation Strategy (REMS) program. You, your healthcare provider, and your pharmacy must be enrolled in this program.
Your healthcare provider will discuss the program with you, give you an opportunity to ask questions, and ask you to sign a "Patient-Prescriber Agreement." The pharmacy will enroll you in the program the first time you fill your Lazanda prescription.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed July 19, 2011.
National Library of Medicine (US). Drugs and Lactation Database (LactMED). NLM Web site. Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. Accessed July 19, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click